Immunobiology of primary intracranial tumors (original) (raw)
Related papers
Human glioma-associated antigens detected by monoclonal antibodies
Cancer research, 1981
Hybridoma cells were derived from a fusion between mouse P3x63/Ag8 myeloma cells and spleen cells from a mouse immunized with whole cells of a human malignant glioma line. Of 345 hybrids obtained, 36 secreted antibodies that reacted with the glioma cell line used for immunization as assayed by an indirect antibody-binding radioimmunoassay. After a first screening for the absence of reactivity on two nongliogenous cell lines, 3 hybrids were selected and cloned by limiting dilution. The specificity of these monoclonal antibodies was then investigated on a panel of 18 cell lines derived from human malignant gliomas, 18 cell lines from nongliogenous neoplasms, as well as normal peripheral blood lymphocytes, normal skin fibroblasts, and normal spermatozoa. The monoclonal antibodies from two positive hybrids, BF7 and GE2, reacted exclusively with glioma cells and appeared to be directed against common malignant glioma antigen(s). BF7 antibodies bound to 13 and GE2 to 17 of 18 glioma cell ...
Long-term immunological investigation of malignant intracranial gliomas
Surgical Neurology, 1981
In ihi* ~tudy, 118 cor~,~:~tive adult lemients with supralenmriM Rliomas undrr~ent Vr¢o~:ra6vv im-munol~deal monitoring, with particular regard to B-Iym#ocy|e arid T-|ymph~yte marker--, MOst patlcnt., were treated suvMrall}" a~d whh r~dh)thceapg, ~lree month~ bier, they were rradmim.d fi-,r ~t~.~+rative im-munolo#eM inve:ligation ar~J {d|oiv.up control A IOta| of 76 ras¢~ could thus ~ complctelg in~'e.~filaaled and urre stalls||rally di#hle foe evahatation, A pronounced i;,ilure o{ T+cel~mediatrd immunity was observed: "E+activc" rose~te-fo~ming cells and milo~en+inducrd bta,~o~etm~i.~ testx tum~ ~ui to be mark¢dly drprcs.~,-'d+ with a s|ight r~,¢or~rat~-¢ recovery+ Spo~tanc~o~ re|l-mediated ¢ylo* to,icily war. sigltificant|y ~p < 0.01) inctca~+:d both in preoptaratlve and F~st,)pera|i+,e findinl~+ TRy mat= immunodia[.mostic t-,atterft.~ (immurtog|oba tins a s~av+ :,o ~acc immun~lnbulin+-, "mou~e '+ r,a.,,elte:,| ¢,.,nOert~ln~ the B+ cell+dependent "Ix,hi +' were found to Ix+ ~dthin norma| }imits, G~t+.++-a M N.~.~+++:..au+ ++ +*+ A~+~*. £+?+ ++ + Oh+++ A+ R,.++th++ A+ Z+~+c¢++++. ' :ih, ++' ,L h.,+,c+ t.i+ l +++¢++++. +m+ m:+ IIIU++O~i~+(++} ++IpC~t+|~++I++I+ ~+ mahOi+++++~ +I++++ tcfa++~,+~ Chorea+.. S~+t~ Neutol |O aS+ 52, 1!+8t v+mf~ ++. y. +. I++. m {(.+TN+S) }lave ~+el'~ t~:Fu+)lled t+~ :,how V+ part~¢lilar dcp~ex<o~ ~f ce||-:n,ediated immum~y {2+ 4+ 9+ t L 18. 2i.
Acta Neurochirurgica, 1982
The authors studied 24 patients affected by anaplastic gliomas as regards immunology. In all of them the authors evaluated the lymphocyte subpopulation (B and T), firstly by simple lymphocyte count, secondly by studying the rosettes E-total and EAC, thirdly by stimulating the lymphocytes with mitogens phytohaemoagglutinin-P (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM), and lastly by counting the release of Cr 51 in Chang liver cells culture in order to obtain antibody dependent cellular cytotoxicity (ADCC). The parameters were also evaluated after surgery and during conventional radio-chemotherapy with BCNU. Whereas the so-called B-pool seems to be unaffected, the preliminary results show that the T-pool (identified by the E-t rosettes and by responses to PHA, PWM, and ConA) is depressed to a statistically significant degree, if compared with a control group. This depression seems to be related to the tumoral mass, and it is not increased by radio-chemotherapy. In addition, ADCC also seems to be depressed in our glioma patients in comparison with a control group and with a group of bladder concer patients.
Autologous serologic responses in glioma patients correlation with tumor grade and survival
Cancer, 1983
The serologic responses of 42 patients with gliomas have been evaluated in a quantitative microcytotoxicity assay utilizing autologous cultured glioma cells. Forty-five percent of patients had detectable cytotoxic antibody apparently directed to their own cultured cells. When tumor grade was correlated with immune response, 15/20 patients with Grade I, I1 and 111 astrocytomas had antigens detectable in autologous sera whereas only 5/22 patients with Grade IV astrocytomas had such responses. None of the autologous fibroblasts from the 15 patients with paired gliomas and fibroblast lines had membrane antigens detectable using autologous sera and fibroblast absorption did not reduce antiglioma activity. Thus, the cytotoxicity observed in this assay appears to be restricted to tumor cells, suggesting reactivity against tumorassociated antigen. In addition, it appears that these immune responses are highly correlated with survival in primary malignant brain tumor patients. Cancer 52:2230-2235. 1983. OTH SEROLOGIC and cellular immunological studies B have provided evidence for several classes of antigens on the surface of human glioma cells. Pfreundschuh et al.' and Coakham et aL2 with an adsorption analysis technique utilizing various target cell assays including mixed hemadsorption assay (MHA), immune adherence assay (IA), an antLC3-MHA mixed hemadsorption assay (C3-MHA) and a protein A assay (PA) have defined a complex of glioma surface antigens. Categories defined include (1) highly restricted or individually distinct tumor antigens; (2) common glioma antigens; (3) brain and fibroblast-associated oncofetal antigens; and (4) neuroectodermal-derived antigens. In addition, these and other
Immunological monitoring of brain tumour patients
International Surgery Journal, 2018
Background: Patient suffering from CNS tumours are among the best suited as regards the study of their immunologic status is concerned because these tumours rarely metastasize and general condition of patient is not much affected. Extensive research has been done on immunological response in neoplasms of other organs, but immunology of CNS tumours studied mainly during last five decades. It is now realized that immunologic reactions may be important in the development and growth of the CNS tumours. Although there is evidence that immunotherapy is helpful in control of some solid tumours but adequate knowledge of the immunology of glial tumours to guide the rational treatment is not yet available. Methods: This study was conducted on 60 cases that included 20 controls and 40 patients of primary intracranial brain tumors admitted to neurosurgical services of University Hospital, Banaras Hindu University, Varanasi during the period of January 1987 to January 1988. Results: The study r...
Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry, 2010
Immunotherapy of brain tumors is rapidly emerging as a potential clinical option [1-3]. The quality and magnitude of immune responses evoked by the new generation anti-tumor vaccines is in general highly dependent on the source or choice of peptide antigens, and as well, a suitable immunopotentiator. Poorly immunogenic antigens, such as those present in tumor cell lysates, may not reliably provide stimulation like recombinant or DNA-encoded protein antigens might be expected to. In addition, the efficacy of the vaccine may depend on inherent counteracting measures of the tumor which dampen immune surveillance and immune effector activity triggered by immunization [4]. Our body has many means of limiting an immune response to our own (self) proteins. In particular, patients with gliomas exhibit a broad suppression of cell-mediated immunity [5-8]. Unfortunately, for most tumor vaccines the induction of local or systemic immune effector cells does not necessarily translate into objecti...
Neoplastic Brain, Glioblastoma, and Immunotherapy
Brain and Spinal Tumors - Primary and Secondary, 2020
IGF-I, insulin-like growth factor 1, is present in normal fetal/neonatal brain development and reappears in the mature brain participating in the development of malignant tumor, glioblastoma multiforme. Targeting the IGF-I system has emerged as a useful method to reduce glial malignant development. Downregulation in the expression of IGF-I using antigene anti-IGF-I technology (antisense, AS, and triple helix, TH) applied in glioma cell culture established from glioblastoma biopsies induces the expression of B7 and MHC-I antigens in transfected cells (immunogenicity). The transfected cancer cells, "vaccines," after subcutaneous injection, initiated an immune response mediated by T CD8+ lymphocytes, followed by tumor regression (immunotherapy). The median survival of patients treated by surgery followed by radiotherapy and immunotherapy was 21-24 months. On the other side, the experimental work has demonstrated that IGF-I AS or TH transfected tumor cells fused with activated dendritic cells, DC, showing more striking immunogenic character. Using IGF-I TH/DC "vaccination," the efficiency in suppressing rat glioma tumors is not only relatively higher than that obtained using IGF-I TH cells but is also more rapid.